Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Assets (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Other Non-Current Assets over the past 12 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $1.5 million for Q4 2025, up 206.59% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 206.59% YoY), and the annual figure for FY2025 was $1.5 million, up 206.59%.
  • Other Non-Current Assets for Q4 2025 was $1.5 million at Viridian Therapeutics, Inc.\DE, up from $1.5 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for VRDN hit a ceiling of $1.5 million in Q1 2022 and a floor of $1000.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $982000.0 (2022), compared with a mean of $944100.0.
  • Biggest five-year swings in Other Non-Current Assets: surged 154100.0% in 2022 and later plummeted 44.34% in 2024.
  • Viridian Therapeutics, Inc.\DE's Other Non-Current Assets stood at $1.5 million in 2021, then crashed by 34.14% to $982000.0 in 2022, then plummeted by 38.49% to $604000.0 in 2023, then fell by 17.05% to $501000.0 in 2024, then skyrocketed by 206.59% to $1.5 million in 2025.
  • The last three reported values for Other Non-Current Assets were $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $506000.0 (Q2 2025) per Business Quant data.